|
1
|
Shields CL, Furuta M, Thangappan A, Nagori
S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade
OA, et al: Metastasis of uveal melanoma millimeter-by-millimeter in
8033 consecutive eyes. Arch Ophthalmol. 127:989–998. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chattopadhyay C, Kim DW, Gombos DS, Oba J,
Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, et
al: Uveal melanoma: From diagnosis to treatment and the science in
between. Cancer. 122:2299–2312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shaughnessy M, Klebanov N and Tsao H:
Clinical and therapeutic implications of melanoma genomics. J
Transl Genet Genom. 2:142018.
|
|
4
|
Singh AD and Topham A: Incidence of uveal
melanoma in the United States: 1973-1997. Ophthalmology.
110:956–961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaliki S and Shields CL: Uveal melanoma:
Relatively rare but deadly cancer. Eye (Lond). 31:241–257. 2017.
View Article : Google Scholar
|
|
6
|
Grisanti S and Tura A: Uveal melanoma.
Noncutaneous melanoma. Scott JF and Gerstenblith MR: Codon
Publications; Brisbane: 2018, View Article : Google Scholar
|
|
7
|
Eskelin S, Pyrhönen S, Hahka-Kemppinen M,
Tuomaala S and Kivelä T: A prognostic model and staging for
metastatic uveal melanoma. Cancer. 97:465–475. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Field MG, Durante MA, Anbunathan H, Cai
LZ, Decatur CL, Bowcock AM, Kurtenbach S and Harbour JW: Punctuated
evolution of canonical genomic aberrations in uveal melanoma. Nat
Commun. 9:1162018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Augsburger JJ, Corrêa ZM and Shaikh AH:
Effectiveness of treatments for metastatic uveal melanoma. Am J
Ophthalmol. 148:119–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Desjardins L, Levy C, Lumbroso Le Rouic L,
Cassoux N, Piperno-Neumann S, Mariani P, Servois V, Dendale R,
Plancher C and Asselain B: Adjuvant intravenous therapy by
fotemustine in uveal melanoma: A randomised study. Acta
Ophthalmologica. Sep 15–2011.Epub ahead of print. View Article : Google Scholar
|
|
11
|
Komatsubara KM and Carvajal RD:
Immunotherapy for the treatment of uveal melanoma: Current status
and emerging therapies. Curr Oncol Rep. 19:452017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jovanovic P, Mihajlovic M,
Djordjevic-Jocic J, Vlajkovic S, Cekic S and Stefanovic V: Ocular
melanoma: An overview of the current status. Int J Clin Exp Pathol.
6:1230–1244. 2013.PubMed/NCBI
|
|
13
|
Stewart TA, Yapa KT and Monteith GR:
Altered calcium signaling in cancer cells. Biochim Biophys Acta.
1848:2502–2511. 2015. View Article : Google Scholar
|
|
14
|
Brzozowski JS and Skelding KA: The
multi-functional calcium/calmodulin stimulated protein kinase
(CaMK) family: Emerging targets for anti-cancer therapeutic
intervention. Pharmaceuticals (Basel). 12. pp. 122019, View Article : Google Scholar
|
|
15
|
Cui C, Merritt R, Fu L and Pan Z:
Targeting calcium signaling in cancer therapy. Acta Pharm Sin B.
7:3–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Liu H, Xu Y, Xie J, Zhu D, Amos
CI, Fang S, Lee JE, Li X, Nan H, et al: Genetic variants in the
calcium signaling pathway genes are associated with cutaneous
melanoma-specific survival. Carcinogenesis. 40:279–288. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nussinov R, Wang G, Tsai CJ, Jang H, Lu S,
Banerjee A, Zhang J and Gaponenko V: Calmodulin and PI3K signaling
in KRAS cancers. Trends Cancer. 3:214–224. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maiques O, Barceló C, Panosa A, Pijuan J,
Orgaz JL, Rodriguez-Hernandez I, Matas-Nadal C, Tell G, Vilella R,
Fabra A, et al: T-type calcium channels drive migration/invasion in
BRAFV600E melanoma cells through Snail1. Pigment Cell Melanoma Res.
31:484–495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Umemura M, Baljinnyam E, Feske S, De
Lorenzo MS, Xie LH, Feng X, Oda K, Makino A, Fujita T, Yokoyama U,
et al: Store-operated Ca2+ entry (SOCE) regulates
melanoma proliferation and cell migration. PLoS One. 9:e892922014.
View Article : Google Scholar
|
|
20
|
Chen X, Wu Q, Depeille P, Chen P, Thornton
S, Kalirai H, Coupland SE, Roose JP and Bastian BC: RasGRP3
mediates MAPK pathway activation in GNAQ mutant uveal melanoma.
Cancer Cell. 31:685–696.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie S, Naslavsky N and Caplan S:
Diacylglycerol kinases in membrane trafficking. Cell Logist.
5:e1078431. 2015. View Article : Google Scholar
|
|
22
|
Opie LH: Pharmacological differences
between calcium antagonists. Eur Heart J. 18(Suppl A): A71–A79.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Das A, Pushparaj C, Bahí N, Sorolla A,
Herreros J, Pamplona R, Vilella R, Matias-Guiu X, Martí RM and
Cantí C: Functional expression of voltage-gated calcium channels in
human melanoma. Pigment Cell Melanoma Res. 25:200–212. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Striessnig J, Ortner NJ and Pinggera A:
Pharmacology of L-type calcium channels: Novel drugs for old
targets? Curr Mol Pharmacol. 8:110–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou J, Li Y, Fan HQ and Wang JG: Effects
of dihydropyridine calcium channel blockers on oxidized low-density
lipoprotein induced proliferation and oxidative stress of vascular
smooth muscle cells. BMC Res Notes. 5:1682012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee H, Kang S and Kim W: Drug
repositioning for cancer therapy based on large-scale drug-induced
transcriptional signatures. PLoS One. 11:e01504602016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ohba T, Watanabe H, Murakami M,
Radovanovic M, Iino K, Ishida M, Tosa S, Ono K and Ito H:
Amlodipine inhibits cell proliferation via PKD1-related pathway.
Biochem Biophys Res Commun. 369:376–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
